Cancer

CG Oncology reports 68% lower recurrence risk in bladder cancer trial

Cretostimogene cut recurrence risk by 68% after surgery in a Phase 3 trial of patients with non-muscle invasive bladder cancer, CG Oncology said.

Reported by 3 outlets Tuesday, November 17, 2026

Cancer cells under a fluorescence microscope
Photo: CC0

CG Oncology said its immunotherapy cretostimogene grenadenorepvec succeeded in a Phase 3 trial in certain patients with non-muscle invasive bladder cancer. BioPharma Dive and STAT reported that treatment after surgery cut the risk of tumor recurrence by 68%. The cancer has not spread beyond the bladder’s inner lining, according to BioPharma Dive.

BioPharma Dive reported that these tumors are usually treated with BCG after tumor resection, but the disease can return. The company said the latest results will support an application next year for a setting with no therapeutic option. CG is also preparing an approval request for patients whose cancer has not responded to BCG, and expects to complete that filing early next year, according to BioPharma Dive.

Reporting on this story

More top stories

This Week in Medicine

The week in medicine, in five minutes

The most important medical news of the week, summarized for you and easy to read. Every Sunday, free.

Free. No spam. Unsubscribe anytime.